Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...
Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...
Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...
BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...
MedPage Today on MSN1d
STRIDE: Semaglutide Shows it Has Legs in Peripheral Artery DiseaseCHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that ...
BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...
Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...
The Health and Medical Education Department has informed Jammu and Kashmir that it has no proposal for the execution of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback